All news from Nuclear Medicine

Neuroimaging Findings of Alzheimer’s Disease

Already affecting more than five million Americans older than 65, Alzheimer's disease is on the rise and expected to impact more than 13 million people by 2050. Over the last three decades, researchers have relied on neuroimaging brain scans such as magnetic resonance imaging (MRI) or positron emission tomography (PET) to study Alzheimer's disease and other neurodegenerative diseases. 

SPECT Brain Radiotracer for the GnRH Receptor

Disturbance of gonadotropin-releasing hormone (GnRH) signaling is implied in a variety of human diseases spanning from reproductive diseases, hormone-dependent oncological diseases, and neurodegenerative diseases. GnRH receptor (GnRH-R) play a central role in this context and have consequently attracted considerable interest as therapeutic targets

New PET Tracer Identified For Imaging Tau in Alzheimer's Disease Patients

In the diagnosis of Alzheimer's disease and the search for effective treatments, tau tangles in the brain have joined amyloid build-up as markers of the disease and potential therapeutic targets. In the December issue of The Journal of Nuclear Medicine, the featured article of the monthly reports on the identification of a promising second-generation positron emission tomography (PET) tracer for imaging and measuring tau pathology